Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ready, steady, glow

Researchers at Stanford University School of Medicine have developed an advanced activity-based probe they say will allow drug companies to make faster, earlier and perhaps even cheaper decisions about the specificity and activity of preclinical compounds.

The researchers last week published a study in Nature Chemical Biology showing that a new class of activity-based probes, which they call quenched near-infrared fluorescent ABPs

Read the full 622 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE